Literature DB >> 22733740

p85β phosphoinositide 3-kinase subunit regulates tumor progression.

Isabel Cortés1, Jesús Sánchez-Ruíz, Susana Zuluaga, Vincenzo Calvanese, Miriam Marqués, Carmen Hernández, Teresa Rivera, Leonor Kremer, Ana González-García, Ana C Carrera.   

Abstract

PIK3R2 encodes a ubiquitous regulatory subunit (p85β) of PI3K, an enzyme that generates 3-polyphosphoinositides at the plasma membrane. PI3K activation triggers cell survival and migration. We found that p85β expression is elevated in breast and colon carcinomas and that its increased expression correlates with PI3K pathway activation and tumor progression. p85β expression induced moderate PIP(3) generation at the cell membrane and enhanced cell invasion. In accordance, genetic alteration of pik3r2 expression levels modulated tumor progression in vivo. Increased p85β expression thus represents a cellular strategy in cancer progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733740      PMCID: PMC3396516          DOI: 10.1073/pnas.1118138109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

Review 1.  Phosphoinositide 3-kinase controls early and late events in mammalian cell division.

Authors:  Zaira García; Amit Kumar; Miriam Marqués; Isabel Cortés; Ana C Carrera
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

2.  High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.

Authors:  Lydia W T Cheung; Bryan T Hennessy; Jie Li; Shuangxing Yu; Andrea P Myers; Bojana Djordjevic; Yiling Lu; Katherine Stemke-Hale; Mary D Dyer; Fan Zhang; Zhenlin Ju; Lewis C Cantley; Steven E Scherer; Han Liang; Karen H Lu; Russell R Broaddus; Gordon B Mills
Journal:  Cancer Discov       Date:  2011-06-07       Impact factor: 39.397

3.  Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.

Authors:  Ji Luo; Cassandra L Sobkiw; Nicole M Logsdon; John M Watt; Sabina Signoretti; Fionnuala O'Connell; Eyoung Shin; Youngju Shim; Lily Pao; Benjamin G Neel; Ronald A Depinho; Massimo Loda; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

4.  Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement.

Authors:  Saskia M Brachmann; Claudine M Yballe; Metello Innocenti; Jonathan A Deane; David A Fruman; Sheila M Thomas; Lewis C Cantley
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

5.  Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival.

Authors:  Kohjiro Ueki; David A Fruman; Saskia M Brachmann; Yu-Hua Tseng; Lewis C Cantley; C Ronald Kahn
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

Review 6.  Targeting phosphoinositide 3-kinase: moving towards therapy.

Authors:  Romina Marone; Vladimir Cmiljanovic; Bernd Giese; Matthias P Wymann
Journal:  Biochim Biophys Acta       Date:  2007-10-12

7.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

Authors:  A J Philp; I G Campbell; C Leet; E Vincan; S P Rockman; R H Whitehead; R J Thomas; W A Phillips
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

Review 8.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

9.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function.

Authors:  M P Myers; I Pass; I H Batty; J Van der Kaay; J P Stolarov; B A Hemmings; M H Wigler; C P Downes; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

10.  p85beta phosphoinositide 3-kinase regulates CD28 coreceptor function.

Authors:  Isabela Alcázar; Isabel Cortés; Angel Zaballos; Carmen Hernandez; David A Fruman; Domingo F Barber; Ana C Carrera
Journal:  Blood       Date:  2009-02-03       Impact factor: 22.113

View more
  33 in total

1.  Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity.

Authors:  Vicente Pérez-García; Javier Redondo-Muñoz; Amit Kumar; Ana C Carrera
Journal:  Mol Cell Biol       Date:  2014-06-23       Impact factor: 4.272

2.  Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease.

Authors:  José R Naranjo; Hongyu Zhang; Diego Villar; Paz González; Xose M Dopazo; Javier Morón-Oset; Elena Higueras; Juan C Oliveros; María D Arrabal; Angela Prieto; Pilar Cercós; Teresa González; Alicia De la Cruz; Juan Casado-Vela; Alberto Rábano; Carmen Valenzuela; Marta Gutierrez-Rodriguez; Jia-Yi Li; Britt Mellström
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

3.  Oncogenic pathway driven by p85β: upstream signals to activate p110.

Authors:  Ling Rao; Lydia W T Cheung
Journal:  Mol Cell Oncol       Date:  2020-07-13

4.  Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K).

Authors:  Yoshihiro Ito; Jonathan R Hart; Lynn Ueno; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

Review 5.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

6.  Conjugation of SUMO to p85 leads to a novel mechanism of PI3K regulation.

Authors:  C F de la Cruz-Herrera; M Baz-Martínez; V Lang; A El Motiam; J Barbazán; R Couceiro; M Abal; A Vidal; M Esteban; C Muñoz-Fontela; A Nieto; M S Rodríguez; M Collado; C Rivas
Journal:  Oncogene       Date:  2015-09-28       Impact factor: 9.867

Review 7.  Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets.

Authors:  Yoshihiro Ito; Jonathan R Hart; Peter K Vogt
Journal:  Expert Opin Ther Targets       Date:  2018-09-24       Impact factor: 6.902

8.  p85β increases phosphoinositide 3-kinase activity and accelerates tumor progression.

Authors:  Ana González-García; Ana C Carrera
Journal:  Cell Cycle       Date:  2012-08-30       Impact factor: 4.534

9.  Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.

Authors:  Britta Weigelt; Julian Downward
Journal:  Front Oncol       Date:  2012-08-31       Impact factor: 6.244

10.  p110δ PI3 kinase pathway: emerging roles in cancer.

Authors:  Niki Tzenaki; Evangelia A Papakonstanti
Journal:  Front Oncol       Date:  2013-03-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.